Breast health belongs in every hormone conversation. Patients who begin hormone therapy often ask what else they can do to support breast tissue—and they deserve answers grounded in evidence, not marketing. This month we look at five supplements with published human data relevant to breast health. The strength of that evidence varies widely, and we present each one honestly. None of these replaces screening, surveillance, or oncology care.

DIM (3,3′-Diindolylmethane)

DIM is the primary active metabolite of indole-3-carbinol from cruciferous vegetables, and its main clinical relevance lies in estrogen metabolism. DIM shifts hepatic estrogen hydroxylation toward the 2-hydroxy pathway and away from the more proliferative 16α-hydroxy pathway—the same ratio many BHRT providers track on urinary metabolite testing. In a 12-month randomized placebo-controlled trial of 130 women taking tamoxifen, DIM at 150 mg twice daily raised the 2/16α-hydroxyestrone ratio and increased SHBG by roughly 25 nmol/L, though breast density did not change. The same trial delivered a critical finding—DIM lowered plasma levels of endoxifen and other active tamoxifen metabolites. DIM favorably modifies estrogen metabolism, but no trial has yet shown it reduces breast cancer incidence.

Clinical Note (Dosing): Trials have used 108 mg daily to 150 mg twice daily of absorption-enhanced DIM, with metabolite testing useful to confirm response.

Safety Considerations: DIM is generally well tolerated; headache, GI upset, and darkened urine occur occasionally. Avoid DIM in patients taking tamoxifen, given its documented reduction of active tamoxifen metabolites, and in pregnancy.

Key References

Thomson, C. A., Chow, H. H. S., Wertheim, B. C., Roe, D. J., Stopeck, A., Maskarinec, G., Altbach, M., Chalasani, P., Huang, C., Strom, M. B., Galons, J. P., & Thompson, P. A. (2017). A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Research and Treatment, 165(1), 97–107. https://doi.org/10.1007/s10549-017-4292-7

Dalessandri, K. M., Firestone, G. L., Fitch, M. D., Bradlow, H. L., & Bjeldanes, L. F. (2004). Pilot study: Effect of 3,3′-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutrition and Cancer, 50(2), 161–167. https://doi.org/10.1207/s15327914nc5002_5

Molecular Iodine

Breast tissue actively concentrates iodine, and molecular iodine (I₂) appears to act on breast tissue through pathways distinct from iodide’s thyroid effects. The clearest clinical evidence involves fibrocystic breast changes and cyclic mastalgia. In a multicenter randomized double-blind trial of 111 euthyroid women with breast pain and fibrosis, molecular iodine produced dose-related pain reduction over 6 months, and more than half of women on 6 mg daily reported clinically significant improvement. Earlier controlled work found molecular iodine produced both subjective and objective improvement in fibrocystic disease with less thyroid impact than sodium iodide. Data suggesting a protective role against breast cancer remain largely preclinical, so iodine fits best as breast-tissue support for symptomatic patients.

Clinical Note (Dosing): Molecular iodine at 3–6 mg daily for at least 3–6 months showed the most consistent benefit for cyclic breast pain.

Safety Considerations: Obtain TSH, free T4, free T3, and thyroid antibodies before starting and monitor periodically. Use caution in autoimmune thyroiditis, nodular thyroid disease, hyperthyroidism, and known iodine sensitivity.

Key References

Kessler, J. H. (2004). The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. The Breast Journal, 10(4), 328–336. https://doi.org/10.1111/j.1075-122X.2004.21341.x

Ghent, W. R., Eskin, B. A., Low, D. A., & Hill, L. P. (1993). Iodine replacement in fibrocystic disease of the breast. Canadian Journal of Surgery, 36(5), 453–460.

Vitamin D3 (Cholecalciferol)

Vitamin D receptors are expressed throughout breast tissue, where vitamin D regulates cell differentiation and proliferation. Observational studies consistently link higher 25(OH)D levels with lower breast cancer risk, but randomized data tell a more nuanced story. The VITAL trial randomized 25,871 adults to 2,000 IU daily or placebo for a median 5.3 years and found no reduction in overall cancer incidence. A secondary analysis, however, showed a 17% reduction in advanced cancers—metastatic or fatal—with the strongest effect in participants of normal weight (HR 0.62). These findings covered all cancer types, not breast cancer specifically. For BHRT providers, correcting deficiency remains a sound foundation of care, with the most compelling signal pointing toward cancer progression rather than prevention.

Clinical Note (Dosing): Typical dosing ranges from 1,000–5,000 IU daily, individualized to serum 25(OH)D and rechecked after 8–12 weeks.

Safety Considerations: Monitor calcium and 25(OH)D at higher doses. Use caution in patients with a history of kidney stones, granulomatous disease, primary hyperparathyroidism, or concurrent thiazide diuretic use.

Key References

Chandler, P. D., Chen, W. Y., Ajala, O. N., Hazra, A., Cook, N., Bubes, V., Lee, I. M., Giovannucci, E. L., Willett, W., Buring, J. E., & Manson, J. E. (2020). Effect of vitamin D3 supplements on development of advanced cancer: A secondary